Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
SSRI (Selective Serotonin Reuptake Inhibitor) — OCD Specialist

Fluvoxamine

Brand names: Faverin

Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) used for depression and obsessive-compulsive disorder.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively inhibits the presynaptic serotonin transporter, increasing synaptic serotonin availability.

Prescribing in practice

  • There is an increased risk of suicidal thoughts and behaviour early in treatment, particularly in younger adults, requiring close monitoring.
  • Fluvoxamine is a potent inhibitor of several cytochrome P450 enzymes, causing clinically important interactions including with theophylline, clozapine and tizanidine.
  • Risk of hyponatraemia, gastrointestinal bleeding and serotonin syndrome rises with concomitant serotonergic drugs, NSAIDs or anticoagulants.

Monitoring

Monitor mood and suicidal ideation early in treatment and review for drug interactions and serotonergic adverse effects.

Counselling the patient

  • Full benefit may take several weeks; continue as prescribed.
  • Report worsening mood or thoughts of self-harm, especially early in treatment.
  • Tell your prescriber about all other medicines because interactions are common; do not stop suddenly.

Evidence & guidelines

SSRIs including fluvoxamine are established first-line pharmacotherapy for depression and OCD in NICE guidance.

Reference: NICE CG31 (OCD); NICE CG90 (Depression); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways